by | May 22, 2024 | Publications
Blood Adv. 2024 May 22:bloodadvances.2024013461. doi: 10.1182/bloodadvances.2024013461. Online ahead of print. NO ABSTRACT PMID:38776433 | DOI:10.1182/bloodadvances.2024013461
by | May 22, 2024 | Publications
Cancer Rep (Hoboken). 2024 May;7(5):e2102. doi: 10.1002/cnr2.2102. ABSTRACT BACKGROUND: Thalidomide-containing regimens cause adverse events (AEs) that may require a reduction in treatment intensity or even treatment discontinuation in patients with multiple myeloma....
by | May 22, 2024 | Publications
F1000Res. 2023 Nov 3;12:476. doi: 10.12688/f1000research.133007.3. eCollection 2023. ABSTRACT Multiple myeloma is a common malignant bone-based disease. Pleural effusions reported in these patients remain rare. It is commonly due to congestive heart disease, pulmonary...
by | May 22, 2024 | Publications
Sci Rep. 2024 May 21;14(1):11593. doi: 10.1038/s41598-024-62298-3. ABSTRACT Multiple myeloma (MM) progression involves diminished tumor antigen presentation and an immunosuppressive microenvironment, characterized by diminished expression of major histocompatibility...
by | May 21, 2024 | Publications
Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e433520. doi: 10.1200/EDBK_433520. ABSTRACT Despite significant improvement in the outcomes of patients with newly diagnosed multiple myeloma (NDMM) with novel therapies, there is still an underserved high-risk (HR)...
by | May 21, 2024 | Publications
Cancer Med. 2024 May;13(10):e7297. doi: 10.1002/cam4.7297. ABSTRACT BACKGROUND: Medical mistrust, rooted in unethical research, is a barrier to cancer-related health care for Black/African American (AA) persons. Understanding trust, mistrust, and health care...
